Maxim McKibben, MD
Urology · Charlotte, NCNPI 1598022089
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 83.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $6,243 and has fallen 71.3% since, to $1,790 in 2025.
Across 323 payments — averaging $45.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Laborie Medical Technologies Corp.$2K
- Coloplast$510
- Neotract Inc.$157
- Antares Pharma, Inc.$50
- Merck$31
- plus $21 from 2 others
What the payments were for
- Consulting fees$1,95013%
- Speaking & faculty fees$4,51331%
- Travel & lodging$1,0117%
- Food & beverage$7,11649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 296 | $12,197 |
| Laborie Medical Technologies Corp. | 3 | $1,624 |
| Coloplast | 18 | $510 |
| Neotract Inc. | 2 | $157 |
| Antares Pharma, Inc. | 1 | $50 |
| Merck | 1 | $31 |
| AbbVie | 1 | $15 |
| Ambu Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$1,244
- GENERAL - THERAPIES$614
- GENERAL ERECTILE DYSFUNCTION$295
- TITAN$159
- AMS 700$149
- AMS 800 Artificial Urinary Sphincter$136
- UroLift$132
- AMS 700 CXR RTE KIT$129
How this compares
$14,589 in reported general payments places this provider in the 85th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 125 | $65,223 |
| Trospium Chloride | 14 | $653 |
| Tamsulosin Hcl | 34 | $537 |
| Cefpodoxime Proxetil | 11 | $396 |
| Ampicillin Trihydrate | 33 | $378 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $297 |
| Oxybutynin Chloride | 11 | $275 |
| Finasteride | 16 | $224 |
| Cephalexin | 26 | $171 |
| Tramadol Hcl | 37 | $59 |
| Ciprofloxacin Hcl | 12 | $57 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Other urology in Charlotte
- Michael KennellyCharlotte$1.3M
- Manish PatelCharlotte$84K
- Kris GastonCharlotte$32K
- Todd CohenCharlotte$18K
- Ornob RoyCharlotte$17K
- Robert LippittSmithfield$11.4M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.